MBX Biosciences develops precision-engineered peptide therapies via its proprietary Precision Endocrine Peptide™ (PEP™) platform designed to extend time-action profiles, provide consistent tissue exposure, and enable less frequent dosing. Its lead candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in a Phase 2 trial for chronic hypoparathyroidism, with topline results expected in the third quarter of 2025. MBX 1416, aimed at post-bariatric hypoglycemia, is in a Phase 1 single- and multiple-ascending dose trial with topline data expected in the fourth quarter of 2024. The company also advances an obesity portfolio including MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug in IND-enabling studies, plus multiple discovery and preclinical candidates. MBX says proceeds from its recent financing will support operations into 2026 and fund progression of its clinical and early-stage programs. The company is based in Carmel, Indiana. MBX Biosciences is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide (PEP) therapeutic candidates for endocrine disorders. Its lead candidate, MBX 2109, is a long-acting parathyroid hormone peptide prodrug designed for once-weekly dosing and is in a Phase 1 trial for hypoparathyroidism; MBX 2109 received FDA Orphan Drug designation in July 2022. Proceeds from the financing will support continued clinical advancement of MBX 2109, the preclinical program MBX 1416, and discovery programs in endocrine diseases. The company positions its PEP platform to overcome limitations of traditional peptide therapeutics by delivering sustained activity and improved pharmaceutical properties. MBX says its goal is to simplify disease management and improve outcomes and quality of life for patients with endocrine disorders. MBX is based in Carmel, Indiana. MBX Biosciences is a biotechnology company creating therapies for rare endocrine diseases with a focus on peptide therapeutics. The company advances a preclinical pipeline of peptide candidates directed at clinically validated molecular targets. MBX's platform and drug candidates are built on medicinal expertise and chemical technologies invented at the Indiana University laboratory of Professor Richard DiMarchi, who is co-founder and chief scientific officer. The company intends to advance its candidates toward clinical investigation to address endocrine disorders with substantial unmet medical need. MBX's leadership team, including president and CEO Kent Hawryluk, previously collaborated on successful endocrine drugs such as Humalog and Forteo. The company is based in Carmel, Indiana and is supported by leading life-science investors including Frazier Healthcare Partners, OrbiMed, and New Enterprise Associates. MBX Biosciences develops therapeutics aimed at rare endocrine disorders that the company says represent substantial unmet medical need. The company is pursuing initial discovery research to identify drug candidates with potential life‑saving properties against these disorders. MBX was founded by Indiana University Bloomington Distinguished Professor Richard DiMarchi, IUPUI alumnus Kent Hawryluk, and Tim Knickerbocker, and maintains several ties with Indiana University. The startup has an agreement to support research at the DiMarchi Laboratory in Bloomington and is a sponsor of IU‑based research. MBX completed an initial $2.5 million financing to fund its early discovery work. The leadership team has prior experience pairing on Marcadia Biotech and MB2, both acquired by large pharma, which the company cites as part of its institutional expertise.

Total raised

$216M

Funding rounds

4

Latest round

Series C

Latest activity

Aug 2024